DDIT3 and diffuse large B-cell lymphoma: Further, our biomarker data are hypothesis generating for potential identification of certain subgroups of Chinese patients with non‐GCB DLBCL who might experience improved response with ibrutinib+R‐CHOP versus placebo+R‐CHOP treatment.